CRSP vs. JPM
CRSP (CRISPR Therapeutics AG) and JPM (JPMorgan Chase & Co.) are both stocks. CRSP operates in Biotechnology (Healthcare), while JPM operates in Banks - Diversified (Financial Services). Over the past 5 years, CRSP returned -17.08%/yr vs 17.82%/yr for JPM. At a 0.20 correlation, their price movements are largely independent.
Performance
CRSP vs. JPM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRSP achieves a -5.03% return, which is significantly lower than JPM's 0.50% return.
CRSP
- 1D
- -0.86%
- 1M
- 2.87%
- YTD
- -5.03%
- 6M
- -12.14%
- 1Y
- 20.41%
- 3Y*
- -6.43%
- 5Y*
- -17.08%
- 10Y*
- —
JPM
- 1D
- 2.31%
- 1M
- 7.69%
- YTD
- 0.50%
- 6M
- 1.66%
- 1Y
- 23.40%
- 3Y*
- 34.22%
- 5Y*
- 17.82%
- 10Y*
- 21.02%
CRSP vs. JPM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics AG | -5.03% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 151.39% | 113.18% | 21.68% | 15.89% |
JPM JPMorgan Chase & Co. | 0.50% | 37.27% | 44.29% | 30.63% | -12.64% | 27.75% | -5.53% | 47.26% | -6.62% | 26.76% |
Correlation
The correlation between CRSP and JPM is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2016 | 0.20 |
Fundamentals
CRSP:
$4.78B
JPM:
$896.00B
CRSP:
-$6.24
JPM:
$21.08
CRSP:
1.11K
JPM:
3.14
CRSP:
2.64
JPM:
2.60
CRSP:
$4.10M
JPM:
$285.09B
CRSP:
-$171.17M
JPM:
$173.52B
CRSP:
-$509.21M
JPM:
$81.46B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRSP vs. JPM — Risk / Return Rank
CRSP
JPM
CRSP vs. JPM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and JPMorgan Chase & Co. (JPM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRSP | JPM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.68 | ||
| Sortino ratioReturn per unit of downside risk | -0.49 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.18 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 0.49 | 1.42 | -0.93 |
| Martin ratioReturn relative to average drawdown | 0.81 | 3.36 | -2.54 |
Loading charts...
Drawdowns
CRSP vs. JPM - Drawdown Comparison
The maximum CRSP drawdown since its inception was -85.11%, which is greater than JPM's maximum drawdown of -76.16%. Use the drawdown chart below to compare losses from any high point for CRSP and JPM.
Loading charts...
Drawdown Indicators
| CRSP | JPM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.11% | -76.16% | -8.95% |
Max Drawdown (1Y)Largest decline over 1 year | -42.25% | -15.47% | -26.78% |
Max Drawdown (3Y)Largest decline over 3 years | -64.91% | -24.42% | -40.49% |
Max Drawdown (5Y)Largest decline over 5 years | -80.68% | -38.77% | -41.91% |
Max Drawdown (10Y)Largest decline over 10 years | — | -43.63% | — |
Current DrawdownCurrent decline from peak | -76.29% | -3.66% | -72.63% |
Average DrawdownAverage peak-to-trough decline | -49.24% | -17.62% | -31.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.51% | 6.54% | +18.97% |
Volatility
CRSP vs. JPM - Volatility Comparison
CRISPR Therapeutics AG (CRSP) has a higher volatility of 18.22% compared to JPMorgan Chase & Co. (JPM) at 6.35%. This indicates that CRSP's price experiences larger fluctuations and is considered to be riskier than JPM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRSP | JPM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.22% | 6.35% | +11.87% |
Volatility (6M)Calculated over the trailing 6-month period | 43.62% | 16.67% | +26.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.44% | 21.76% | +40.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 60.65% | 24.46% | +36.19% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.35% | 27.39% | +36.96% |
Dividends
CRSP vs. JPM - Dividend Comparison
CRSP has not paid dividends to shareholders, while JPM's dividend yield for the trailing twelve months is around 1.84%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics AG | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
JPM JPMorgan Chase & Co. | 1.84% | 1.72% | 1.92% | 2.38% | 2.98% | 2.34% | 2.83% | 2.37% | 2.54% | 1.91% | 2.13% | 2.54% |
Financials
CRSP vs. JPM - Financials Comparison
This section allows you to compare key financial metrics between CRISPR Therapeutics AG and JPMorgan Chase & Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRSP and JPM have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRSP has higher volatility (18.22%) compared to JPM (6.35%). In terms of maximum drawdown, CRSP dropped -85.11% vs JPM's -76.16%.
JPM currently has the higher Sharpe Ratio (1.01 vs 0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRSP and JPM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer